Orchid Pharma

Stocks to Watch, Nov 26: Here is a list of stocks that will be in focus for today's session

The collaboration aims to tackle AMR in India by focusing on tier 2 and tier 3 cities, bridging the gap between awareness and action, and ensuring sustainable AMR interventions

The Earnings before interest, tax, depreciation, and amortisation (Ebitda) for the second quarter stood at Rs 30 crore as compared to Rs 24 crore a year ago which implies a rise of 25 per cent

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official. Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs). Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI. "This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,

Shares of Orchid Pharma soared up to 7.69 per cent, hitting its 52-week high at Rs 1,591.55 per share on the BSE in Tuesday's early morning deals

The rise came following Orchid Pharma's announcement of a collaboration with pharmaceutical giant Cipla to introduce the antibiotic Cefepime-Enmetazobactam in India

The partnership between Orchid Pharma and Cipla combines Orchid's innovative drug development capabilities with Cipla's extensive distribution network and market presence

Orchid Pharma has received DCGI's approval for the manufacturing and marketing its invented, made-in-India Active Pharmaceutical Ingredient (API), Enmetazobactam

PRESCRIPTION FOR CAUTION: Analysts sound alarm on valuations after past year's recovery

Orchid Pharma on Wednesday said stock exchanges have started freezing the shares of its promoters for the company's failure to comply with market regulator Sebi's minimum public shareholding norms within the stipulated time period. Under Sebi norms, listed companies are required to have a Minimum Public Shareholding (MPS) of 25 per cent and stock exchanges can take action against companies, including freezing of promoters' shares, for non-compliance. In a regulatory filing, the company said its directors have been informed that they shall not hold any new position as director in any other listed entity. "The Directors at the meeting of Board of Directors held on May 10, 2023, have been informed that they shall not hold any new position as director in any other listed entity and that the action of freezing has been initiated by the stock exchanges against the promoters and promoters," Orchid Pharma said. The company stated that in its effort to maintain minimum public shareholding a

Drug firm Orchid Pharma on Thursday said its board has approved to raise Rs 500 crore from institutional investors. The company's board has approved a Qualified Institutional Placement (QIP) programme to raise Rs 500 crore, it said in a regulatory filing. With this QIP, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 per cent stake in it by March 2023. Post a successful turnaround of the Insolvency Bankruptcy Code case, the company has been on a growth spree, it said. On the back of a robust product launch pipeline and an agile management team, the company said it is poised to become an even stronger player in the Cephalosporin antibiotics space.

Rising Chinese labour costs, geopolitics, pandemic-stricken uncertainties have forced global players to derisk

Company says it's returning to profit after takeover by Dhanuka Laboratories under insolvency resolution

/ -- Orchid Pharma today announced their Q2'22 results. Fuelled by increasing sales and a laser sharp focus on costs, Orchid Pharma reported a 36% surge in total revenue from operations while the EBIDTA has jumped by 104% over the quarter ending September 2021. Dhanuka Group, through its pharmaceutical arm, Dhanuka Laboratories Ltd, had taken over the company through the CIRP (Corporate Insolvency Resolution Process) on 31st March 2020. In spite of the COVID-19 Pandemic, the group through its relentless efforts has turned around the business and within a year made the loss-making business profitable. Speaking on the Q2 results, Manish Dhanuka, Managing Director, Orchid Pharma said, "Our revenues have seen a sharp uptick over the last one year. We have focussed on increasing the capacity utilizations while controlling costs. Owing to all the measures we took, bearing fruit, and a strong product pipeline, the results are a sign of positive things to come." In the near future, the ...

Adani Wilmar, Coal India, Dish Tv, Eicher Motors, Grasim, Medplus Health, MTNL, Nagarjuna Fertilizers, PC Jeweller, Railtel, Rajesh Exports, Spandana Sphoorty and SpiceJet to announce results today.

Shares of Orchid Pharma hit 10 per cent lower limit to end at Rs 1,188 on Thursday

Dhanuka Laboratories, one of the promoter of Orchid Pharma proposed to sell in aggregate up to 3.28 million equity shares, representing 8.04 per cent of the total equity share capital of the Company.

New owners have to divest part of their stake of about 98 per cent in the firm, which re-listed in Mumbai in early November after emerging from bankruptcy

Dhanuka Pharmaceuticals that took over the company almost a year ago, nursed it back to health from bankruptcy

Orchid Pharma shares were locked in the upper circuit for the 96th straight trading day